Metabolic immunoengineering approaches to enhance CD8+ T cell-based cancer immunotherapy
- PMID: 39701038
- DOI: 10.1016/j.cels.2024.11.010
Metabolic immunoengineering approaches to enhance CD8+ T cell-based cancer immunotherapy
Abstract
Many cancer immunotherapies rely on robust CD8+ T cells capable of eliminating cancer cells and establishing long-term tumor control. Recent insights into immunometabolism highlight the importance of nutrients and metabolites in T cell activation and differentiation. Within the tumor microenvironment (TME), CD8+ tumor-infiltrating lymphocytes (TILs) undergo metabolic adaptations to survive but compromise their effector function and differentiation. Targeting metabolism holds promise for enhancing CD8+ T cell-mediated antitumor immunity. Here, we overview the metabolic features of CD8+ TILs and their impact on T cell effector function and differentiation. We also highlight immunoengineering strategies by leveraging the Yin-Yang of metabolic modulation for improving cancer immunotherapy.
Keywords: CD8(+) T cell; cancer immunotherapy; metabolic immunoengineering.
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests L.T. is a co-founder, shareholder, and advisor for Leman Biotech. The interests of L.T. were reviewed and managed by EPFL.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
